Outcome of pregnancies in female patients with inflammatory bowel diseases treated with vedolizumab

A Moens, K van Hoeve, E Humblet… - Journal of Crohn's …, 2019 - academic.oup.com
Abstract Background and Aims Vedolizumab is an IgG1 anti-α4β7 integrin antibody
approved for the treatment of inflammatory bowel diseases [IBD], but without clear safety …
被引用次数：65 相关文章

Outcome of Pregnancies in Female Patients With Inflammatory Bowel Diseases Treated With Vedolizumab.

A Moens, K Hoeve, E Humblet… - Journal of Crohn's …, 2019 - search.ebscohost.com
Abstract Background and Aims Vedolizumab is an IgG1 anti-α4β7 integrin antibody
approved for the treatment of inflammatory bowel diseases [IBD], but without clear safety …

[引用][C] Outcome of Pregnancies in Female Patients With Inflammatory Bowel Diseases Treated With Vedolizumab

A Moens, K van Hoeve, E Humblet, JF Rahier… - Journal of Crohn's and …, 2018 - cir.nii.ac.jp
Outcome of Pregnancies in Female Patients With Inflammatory Bowel Diseases Treated With
Vedolizumab | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …

Outcome of pregnancies in female patients with inflammatory bowel diseases treated with vedolizumab

A Moens, E Humblet, JF Rahier… - Journal of Crohn's …, 2019 - repository.uantwerpen.be
Abstract Background and Aims: Vedolizumab is an IgG1 anti-alpha 4 beta 7 integrin
antibody approved for the treatment of inflammatory bowel diseases [IBD], but without clear …
[PDF] academia.edu

[PDF][PDF] Outcome of Pregnancies in Female Patients With Inflammatory Bowel Diseases Treated With Vedolizumab

A Moensa, K van Hoeveb, E Humbletd… - Journal of Crohn's and …, 2019 - academia.edu
Abstract Background and Aims: Vedolizumab is an IgG1 anti-α4β7 integrin antibody
approved for the treatment of inflammatory bowel diseases [IBD], but without clear safety …

Outcome of Pregnancies in Female Patients With Inflammatory Bowel Diseases Treated With Vedolizumab

A Moens, K van Hoeve, E Humblet… - Journal of Crohn's …, 2019 - academic.oup.com
Abstract Background and Aims Vedolizumab is an IgG1 anti-α4β7 integrin antibody
approved for the treatment of inflammatory bowel diseases [IBD], but without clear safety …

Outcome of Pregnancies in Female Patients With Inflammatory Bowel Diseases Treated With Vedolizumab.

A Moens, K van Hoeve, E Humblet… - Journal of Crohn's & …, 2019 - europepmc.org
Methods We conducted a retrospective, multicentre Belgian observational study. Details on
disease activity, prenatal complications, delivery and neonatal outcome were collected …

[引用][C] Outcome of pregnancies in female patients with inflammatory bowel diseases treated with vedolizumab

A Moens, K van Hoeve, E Humblet… - Journal of Crohn's …, 2019 - difusion.ulb.ac.be

Outcome of Pregnancies in Female Patients With Inflammatory Bowel Diseases Treated With Vedolizumab

A Moens, K van Hoeve, E Humblet… - Journal of Crohn's …, 2019 - pubmed.ncbi.nlm.nih.gov
Background and aims Vedolizumab is an IgG1 anti-α4β7 integrin antibody approved for the
treatment of inflammatory bowel diseases [IBD], but without clear safety data during …

Outcome of Pregnancies in Female Patients With Inflammatory Bowel Diseases Treated With Vedolizumab.

A Moens, K van Hoeve, E Humblet… - Journal of Crohn's & …, 2018 - dial.uclouvain.be
Vedolizumab is an IgG1 anti-α4β7 integrin antibody approved for the treatment of
inflammatory bowel diseases [IBD], but without clear safety data during conception …